Humana partners with IBM Watson on AI solution

Health insurance giant Humana is joining forces with IBM Watson to equip Humana’s Employer Group members with a conversational AI solution. 

Under the partnership, Humana will leverage IBM Watson Assistant for Health Benefits, an AI-enabled virtual assistant in the IBM Watson Health cloud, to streamline engagements between agents, employers and Humana’s 1.3 million Employer Group medical members and 1.8 dental members.

The technology uses a conversational assistant to provide information on member benefits, coverage, claims, referrals and healthcare costs. The tool aims to understand health plan eligibility and communicate that information into member conversations, personalizing each answer to the specific member based on their active or future health plan.

By harnessing the power of artificial intelligence fused with embedded analytics in the Watson Health platform, we can help our employer-customers, members, agents and broker partners enhance their knowledge so they can all make more informed decisions,” Chris Hunter, segment president of Humana’s Group and Military Business, said in a statement.

The AI assistant is expected to help members in a number of ways, including: answering questions directly from members quickly and accurately; freeing up customer care representatives for better customer service by assisting Humana employees and call center employees to answer questions; and calculating personalized cost estimates for medical services for members through historical claims and provider data.

“Navigating our health coverage without the right support can potentially serve as a barrier to care,” said Paul Roma, general manager at IBM Watson Health. “An AI-enabled conversational agent that is trained to understand health plan benefits logic can play a role in helping to simplify complex or possibly confusing plan information. We are proud to support Humana in leading the effort to deploy conversational AI to help enhance and improve the consumer experience.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.